Affymetrix Launches GeneAtlas™ Personal Microarray System for Whole-Genome Gene Expression
March 02 2010 - 9:00AM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) today announced the launch of
the GeneAtlas™ System, a complete, personal solution for processing
Affymetrix arrays and characterizing changes in gene expression in
a variety of research applications.
By combining Affymetrix’ market-leading gene expression
technology with the simplest workflow available and an
unprecedented price, the GeneAtlas System extends the power of
whole-genome microarray analysis to researchers who are constrained
by budget or intimidated by the complexity of microarray
systems.
"The GeneAtlas System gives life science researchers like me an
independence we did not have before,” said Steve White, PhD,
technical director of the Professional Science Master of
Biotechnology Program at San Jose State University and one of the
first scientists to use the GeneAtlas System. “It took us less than
two hours to install and required no tools or engineers to help.
That speed and ease of use continues with experiments, which can be
initiated in less than five minutes. On top of that, the size of
the system enables my scientists to do their work even in our small
lab."
The system, which is available immediately, includes all
required instrumentation, training materials, and easy-to-use data
analysis programs that provide biologically relevant results. It’s
designed to meet the needs of researchers with no microarray
experience, as well as low- to medium-throughput service
laboratories, educational laboratories, and emerging markets.
“We see opportunities to develop the microarray gene expression
market by making it more accessible to new users,” said Greg
Fisher, associate director of product marketing, systems and
software, at Affymetrix. “We have bundled everything a researcher
needs in one complete, affordable system.”
The GeneAtlas System utilizes a convenient new array strip
format that enables researchers to interrogate four distinct
samples simultaneously. Array strips are now available in options
that provide comprehensive coverage of the transcribed human,
mouse, or rat genomes for expression profiling. The array strip is
also available for custom array designs through the MyGeneChip™
Custom Array Program. Additional arrays and applications will be
introduced in the future.
“The GeneAtlas System eliminates workflow, data analysis, and
cost barriers to performing whole-genome analysis,” said Kevin
King, president and CEO of Affymetrix. “Affymetrix is providing a
new generation of life science researchers with a system that
offers uncompromised performance.”
For more information on the GeneAtlas System, please visit
www.affymetrix.com/GeneAtlas
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
1,800 systems have been shipped around the world and more than
20,000 peer-reviewed papers have been published using the
technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Cleveland, Ohio, and Singapore. The
company has about 1,100 employees worldwide and maintains sales and
distribution operations across Europe and Asia. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies,” or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2008, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024